ERBB2 and breast carcinoma: An additional report implicated high levels of heparanase in resistance of metastatic breast cancer models to the small-molecule tyrosine kinase inhibitor of HER2 and EGFR, lapatinib, through the activation of a compensatory EGFR-dependent pathway [121].